Vir Biotechnology Has Been Awarded A BARDA Contract Worth Up To $116M For Development Of Pre-Exposure Monoclonal Antibodies For The Prevention Of Influenza Illness And Medical Countermeasures For Other Emerging Pathogens Of Pandemic Potential
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology has been awarded a contract worth up to $116M by the Biomedical Advanced Research and Development Authority (BARDA) for the development of pre-exposure monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens of pandemic potential.
September 29, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The $116M contract from BARDA could potentially boost Vir Biotechnology's revenues and accelerate its research and development efforts in the field of influenza prevention and other pandemic potential pathogens.
The contract from BARDA is a significant financial boost for Vir Biotechnology. It not only provides a substantial amount of funding for the company's research and development efforts, but also validates the company's work in the field of influenza prevention and other pandemic potential pathogens. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100